CDISC today announced three members have joined its Board of Directors: Jonathan Chainey, Dominic Labriola and Rhona O’Donnell each began serving a three-year term at the beginning of the year. Existing Member, Dr. Erik Pulkstenis, now leads the Board as Chair.
Jonathan Chainey is an Executive Director and Global Head, Data Standards & Governance within Data Sciences, Product Development at Roche. He leads a global team accountable for the cross-functional governance and adoption of Roche’s CDISC-aligned global data standards across all Roche sponsored early and late phase clinical trials. Prior to his election to the CDISC Board of Directors, Jonathan served as chair of the CDISC Advisory Council.
Rhona O’Donnell is currently VP, Data Management Systems and Standards at Novo Nordisk, overseeing clinical data standards, clinical data systems and data transformation across the Novo Nordisk value chain. Her experience spans global data management project delivery, EDC/clinical database and data transformation strategy and management, delivery model design, departmental financial and commercial management, clinical risk management, technical system selection and implementation as well as extensive experience in change control and process improvement projects.
Dominic Labriola isChief Data and Analytics Officer of Madrigal Pharmaceuticals. Dr. Labriola has over 35 years’ experience as a drug developer, overseeing and contributing to the global registration of 20 medicines in multiple therapeutic and more than 20 years serving in executive leadership roles at Bristol Meyers Squibb. His interactions with global regulatory agencies have given him a unique understanding of the drug approval process and the importance of quality data to support those filings. An expert in trial designs and leveraging innovative approaches, he possesses a particular appreciation for the importance of data standards to support clinical research.
“We enthusiastically welcome these new board members,” said Erik Pulkstenis, CDISC board Chair. “Their strategic leadership, coupled with decades of experience, will be invaluable as we interact with the talented and engaged CDISC executive leadership driving this important and impactful organization forward.”
“It’s a pivotal time at CDISC as we evolve organizationally to embrace governance of clinical research information standards,” said David Evans, President and CEO, CDISC. “I am delighted to welcome these seasoned leaders who join an active and engaged Board that will deftly guide CDISC on the next stage of our journey.”
Continuing CDISC Board Members include Chair Dr. Erik Pulkstenis, AbbVie; Chair-Elect Chris Decker, d-Wise, Past Chair Pam Howard, ICON; Dr. Wenjun Bao, JMP Life Sciences of SAS Institute Inc.; Dr. David Hardison; Dr. Pandu Kulkarni, Eli Lilly; Dr. Hiroshi Masumoto, Daiichi Sankyo; Dr. Mihoko Okada,Institute of Health Data Infrastructure for All; Dr. Christina Reith, University of Oxford’s Nuffield Department of Population Health (NDPH); non-voting CDISC Advisory Council Chair Dan Crawford, Veeva System; and ex-officio, David Evans, CDISC.
Visit AITechPark for cutting-edge Tech Trends around AI, ML, Cybersecurity, along with AITech News, and timely updates from industry professionals!
